Watch out Clar­itin: Aldeyra an­nounces clean sweep in PhI­II for new al­ler­gy drug

Aldeyra Ther­a­peu­tics’ stock $ALDX is surg­ing af­ter they post­ed sweep­ing re­sults in a Phase III tri­al for their lead ther­a­py.

Aldeyra an­nounced Tues­day that the mol­e­cule, known as re­prox­alap, re­duced the num­ber of times pa­tients with a form of sea­son­al al­ler­gies scratched their eyes af­ter be­ing ex­posed to rag­weed pollen. It al­so suc­cess­ful­ly re­duced tear­ing, red­ness around the eyes, and pa­tient’s score on a scale that mea­sures how se­vere their re­ac­tion was over­all.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER